The financials
BillionToOne, Inc. by the numbers
BillionToOne, Inc. (BLLN) reported revenue of $108M in Q1 2026 (quarter ended March 31, 2026), up 84% from the same quarter a year earlier. That came with a gross margin of 73% and net income of $18M (17% of revenue). For the full year FY2025, revenue was $305M (+100% year on year) and net income $7.5M. Its largest product in 2026-Q1 was Prenatal at $97M, 89% of the disclosed total, just ahead of Oncology at 9.9%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $108M | $59M | +84% |
| Gross profit | $79M | $38M | +108% |
| Operating income | $18M | −$2.3M | to a profit |
| Net income | $18M | −$4.0M | to a profit |
| Diluted EPS | $0.34 | −$0.39 | to a profit |
| Product | Revenue | Share |
|---|---|---|
| Prenatal | $97M | 89% |
| Oncology | $11M | 9.9% |
| Clinical Trial Support And Other Services | $1.1M | 1.1% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $108.4M (+30%)
Segment Latestquarter on quarteryear on year
- Prenatal$96.5M$96.5MQoQ +30%year on year +72%+30%+72%
- Oncology$10.7M$10.7MQoQ +23%year on year +392%+23%+392%
- Clinical Trial Support And Other Services$1.1M$1.1MQoQ +50%year on year +61%+50%+61%
Diagnostics & Research
Ranks #14 of 29 by Smart Score